Earthquake Arrival Association with Backprojection and Graph Theory

The association of seismic wave arrivals with causative earthquakes becomes progressively more challenging as arrival detection methods become more sensitive, and particularly when earthquake rates are high. For instance, seismic waves arriving across a monitoring network from several sources may overlap in time, false arrivals may be detected, and some arrivals may be of unknown phase (e.g., P- or S-waves). We propose an automated method to associate arrivals with earthquake sources and obtain source locations applicable to such situations. To do so we use a pattern detection metric based on the principle of backprojection to reveal candidate sources, followed by graph-theory-based clustering and an integer linear optimization routine to associate arrivals with the minimum number of sources necessary to explain the data. This method solves for all sources and phase assignments simultaneously, rather than in a sequential greedy procedure as is common in other association routines. We demonstrate our method on both synthetic and real data from the Integrated Plate Boundary Observatory Chile (IPOC) seismic network of northern Chile. For the synthetic tests we report results for cases with varying complexity, including rates of 500 earthquakes/day and 500 false arrivals/station/day, for which we measure true positive detection accuracy of > 95%. For the real data we develop a new catalog between January 1, 2010 - December 31, 2017 containing 817,548 earthquakes, with detection rates on average 279 earthquakes/day, and a magnitude-of-completion of ~M1.8. A subset of detections are identified as sources related to quarry and industrial site activity, and we also detect thousands of foreshocks and aftershocks of the April 1, 2014 Mw 8.2 Iquique earthquake. During the highest rates of aftershock activity, > 600 earthquakes/day are detected in the vicinity of the Iquique earthquake rupture zone

Use of accelerometry to investigate physical activity in dogs receiving chemotherapy

Objectives: To perform a preliminary study to assess whether single-agent palliative or adjuvant chemotherapy has an impact on objectively measured physical activity in dogs. Methods: Fifteen dogs with neoplasia (treatment group) wore ActiGraph™ accelerometers for 5-day periods before, during and after receiving single-agent adjuvant or palliative chemotherapy. Mean 5-day total physical activity and time spent in three different intensities of activity (sedentary, light-moderate and vigorous) before, during and after receiving chemotherapy were compared to a group of 15 healthy dogs (control group). Results were also compared within the treatment group across time. Results: Prior to chemotherapy, treated dogs tended to be less active than control dogs. Treatment group dogs were slightly more active at restaging than they were prior to treatment but had similar activity levels to control dogs. Marked effects of chemotherapy on physical activity were not detected. Physical activity was slightly lower in treated dogs during chemotherapy when compared to control dogs but there was a slight increase in physical activity of treated dogs during chemotherapy when compared with pretreatment recordings. There was little change in the mean 5-day total physical activity between treated dogs during chemotherapy and at restaging but a mild decrease in time spent sedentary and increase in time spent in light-moderate activity at this comparison of time points. Clinical Significance: Single-agent adjuvant or palliative chemotherapy had minimal impact on physical activity levels in dogs with neoplasia

Paper Session III-A - Closed Loop Systems

National Aeronautics and Space Administration (NASA) is unique in its search for man made, closed loop life support systems and in its total engineering methods. Short term space travel has given NASA tremendous knowledge in closed loop systems and the vision of extended space travel will require the expansion of this knowledge base. Earth and its surrounding atmosphere has been operating as a closed loop life support system for billions of years. It has gone through many changes to best suit an equilibrium state. In recent years, man has developed to a level where we can effect that state. With this in mind, the task of protecting our life support system on earth and designing the systems for long duration space travel have great communality

Narrow Linewidth DFB Lasers for Cold Atom Technologies

No abstract available

Narrow Linewidth DFB Lasers for Cold Atom Technologies

No abstract available

Response and survival of dogs with proteinuria (UPC > 2.0) treated with angiotensin converting enzyme inhibitors:Treatment of proteinuria (UPC>2.0) with ACEi

Background: Angiotensin-converting enzyme inhibitors (ACEi) are a recommended treatment for glomerular proteinuria. Frequency of response to ACEi and the association of achieving proposed urine protein-to-creatinine ratio (UPC) targets on survival is unknown. Objectives: To determine response rates to ACEi therapy and whether a positive response is associated with improved survival. Animals: Eighty-five dogs with proteinuria (UPC > 2.0). Methods: Retrospective study including dogs (UPC > 2.0) prescribed an ACEi for treatment of proteinuria. Baseline creatinine, albumin, cholesterol, UPC, and systolic blood pressure were recorded, and cases reviewed to track UPC. Treatment response was defined as achieving a UPC of <0.5 or reduction of ≥50% from baseline within 3 months. Outcome data were collected to determine overall and 12-month survival. Results: Thirty-five (41%) dogs responded to ACEi treatment. Treatment response was statistically associated with both median survival time (664 days [95% confidence interval (CI): 459-869] for responders compared to 177 [95% CI: 131-223] for non-responders) and 12-month survival (79% responders alive compared to 28% non-responders). Baseline azotemia or hypoalbuminemia were also associated with a worse prognosis, with odds ratios of death at 12 months of 5.34 (CI: 1.85-17.32) and 4.51 (CI: 1.66-13.14), respectively. In the 25 dogs with normal baseline creatinine and albumin, response to treatment was associated with 12-month survival (92% responders alive compared to 54% non-responders, P = .04). Conclusions and Clinical Importance: When the UPC is >2.0, achieving recommended UPC targets within 3 months appears to be associated with a significant survival benefit. Response to treatment is still associated with survival benefit in dogs with less severe disease (no azotemia or hypoalbuminemia)

Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010‐2019)

Objectives: To describe the incidence, severity and progression of proteinuria over the first 6 months of masitinib treatment in tumour‐bearing dogs without pre‐existing proteinuria. To describe the effect of treatment on urine protein:creatinine and renal parameters in patients with pre‐existing proteinuria. Materials and Methods: Records were reviewed from patients receiving masitinib for neoplasms between June 1, 2010, and May 5, 2019. Patients without pre‐treatment and at least one urine protein:creatinine after ≥7 days treatment were excluded. Signalment, tumours and concurrent diseases, treatments, haematology, biochemistry and urinalysis results before, during and after treatment for up to 202 days were collected. Patient visits were grouped into six timepoints for analysis. Results: Twenty‐eight dogs were included. Eighteen percent of dogs non‐proteinuric at baseline (four of 22) developed proteinuria during treatment, all within 1 month of treatment initiation. One dog developed hypoalbuminaemia, none developed oedema or ascites, azotaemia or were euthanased/died due to proteinuria. Masitinib was immediately discontinued in both dogs in which urine protein:creatinine greater than 2.0 was detected and in both, proteinuria improved. Six dogs with pre‐treatment proteinuria were treated with masitinib, significant worsening of proteinuria did not occur. Neither azotaemia nor severe hypoalbuminaemia occurred. Clinical Significance: Proteinuria, when it occurs, tends to develop within 1 month of masitinib commencement and may progress rapidly. Weekly proteinuria monitoring should be considered for the first month and a urine protein:creatinine greater than 0.5 should prompt reassessment within 1 week. Masitinib treatment can be considered in patients with pre‐treatment proteinuria and does not inevitably cause worsening of proteinuria

The spatiotemporal evolution of granular microslip precursors to laboratory earthquakes

Laboratory earthquake experiments provide important observational constraints for our understanding of earthquake physics. Here we leverage continuous waveform data from a network of piezoceramic sensors to study the spatial and temporal evolution of microslip activity during a shear experiment with synthetic fault gouge. We combine machine learning techniques with ray theoretical seismology to detect, associate, and locate tens of thousands of microslip events within the gouge layer. Microslip activity is concentrated near the center of the system but is highly variable in space and time. While microslip activity rate increases as failure approaches, the spatiotemporal evolution can differ substantially between stick-slip cycles. These results illustrate that even within a single, well-constrained laboratory experiment, the dynamics of earthquake nucleation can be highly complex